GM PHARMA in Europe
The international pharmaceutical company GM PHARMA continues to expand its network of partners and advance toward its strategic goal - expanding operations across Europe, Southeast Asia, South and Central America.
The international pharmaceutical company GM PHARMA participated in one of the most significant events in the pharmaceutical industry - CPHI, which this year was held in Frankfurt, Germany, at the Messe Frankfurt Exhibition Center.
The event, which has been held for more than three decades, represents the largest platform for innovation, data and technology exchange in the pharmaceutical industry.It connects manufacturers of pharmaceutical products and active pharmaceutical ingredients with service providers and purchasing companies from around the world, playing a crucial role in the advancement and development of the global pharmaceutical sector.
GM PHARMA stands as the only pharmaceutical manufacturer from Georgia to proudly represent the country at this prestigious international forum, once again participating with its own dedicated exhibition stand. The exhibition brought together 2,400 exhibitors, 62,000 visitors and more than 250 international expert speakers from nearly 160 countries worldwide.
During the exhibition, GM PHARMA’s representatives held numerous productive business meetings with both existing and potential partners. Strategic focus was directed toward strengthening collaborations in licensing, contract manufacturing, formulation and analytical development and technology transfer.
One of the most notable engagements during the exhibition was the meeting with representatives of the German company - Actrevo GmbH. With over a decade of international experience, Actrevo GmbH serves as a strategic partner to GM PHARMA, supporting the company in ensuring compliance with regulatory processes, strengthening its presence in the EU market and strengthening territorial expansion.
Driven by a mission to improve lives, GM PHARMA places patient health at the heart of everything. The company is dedicated to enhancing quality of life and extending longevity through the development of safe, effective and high-quality pharmaceutical products. The company aims to address unmet medical needs by developing effective therapies for the prevention and treatment of various pathologies.
GM PHARMA is deeply committed to innovation, supported by a robust R&D and product development strategy. With 18 active research projects underway and over 30 new initiatives planned for 2025, the company continues to foster forward-thinking growth. These innovations are expected to significantly enhance the safety and efficacy of treatments across its expanding portfolio.
Today, GM PHARMA’s medicines serve over 14 million patients annually in Georgia and international markets - a testament to the strong trust and recognition the company has earned from both healthcare professionals and patients worldwide.
GM PHARMA - Serving Those Who Need It Most!